• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Preclinical Rheumatoid Arthritis: Pipeline Analysis & Biomarker Insight, H1 2018.

Scope of report

  • The report provides brief overview of Preclinical RA.
  • This report discusses ‘risk factors for development of RA’ and ‘at risk population’.
  • This report provides comparison of ‘at risk population’ and ‘classified RA patients’ based on biomarker analysis.
  • This report discusses lessons learned from animal studies
  • This report elaborates biomarker insight from retrospective human studies
  • The report covers clinical therapeutics in development for preclinical RA including product profiles, trial summaries.
  • The report mentions rational of clinical trial designs and insight from clinical trials.
  • The report elaborates Potential methodologies for investigating preclinical RA.
  • The report features clinical Pipeline insight based on MOA, sponsor & route of administration
  • The report also covers preclinical pipeline insight.
  • The report captures recent news and collaborations in development of therapeutics for preclinical RA

Reasons to buy

  • The report provides brief overview of Preclinical RA.
  • The report provides a snapshot of the global therapeutic landscape of Preclinical RA.
  • The report assesses Preclinical RA pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA) and route of administration (RoA).
  • The report reviews Preclinical RA pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Preclinical RA ranging from discovery to pre-registration and undisclosed stages.
  • The report features descriptive drug profiles for the pipeline products which includes, product briefs, MoA description, rationale of development, clinical trial details with results if published, partnerships activity & current status.

Companies covered

Bristol-Myers Squibb, Johnson & Johnson, Padlock Therapeutics, Cell Therapeutics, ModiQuest Research,

Key Drugs

Abatacept, Hydroxychloroquine, Rituximab, Methotrexate, Atorvastatin

Publisher: Pharmintel

Format: Microsoft word/PDF

Pages: 47


  • Single Use: $1000
  • Site License: $1500
  • Global License: $2000

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel